Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HL Genomics manufactures and supplies a range of active pharmaceutical ingredients—including small molecules like bepotastine—and biologics such as insulin and vaccines. The company holds multiple regulatory registrations for its products in major markets including the US, EU, Japan, Korea. No clinical trial results are reported as it operates primarily as an ingredient/API supplier.
Pipeline Breadth & Programs HL Genomics does not appear to have a traditional R&D pipeline but rather offers a portfolio of commercialized APIs:
| name | stage | modality | target | indication | |--------------|------------|--------------|------------------|---------------------------| | bepotastine | Commercial | Small molecule | Histamine receptor* | Allergic conjunctivitis/rhinitis* | *(Other programs include various antibiotics [erythromycin], hormones [insulin], antimalarials etc.; all at commercial stage)*(Asterisk denotes inference based on standard use/product class.)
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HL Genomics.